相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial
Bruno P. Coudert et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
Steven A. Limentani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
Aman U. Buzdar et al.
CLINICAL CANCER RESEARCH (2007)
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
J Hurley et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer:: results of a multicenter phase II trial
BP Coudert et al.
ANNALS OF ONCOLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
BT Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes
R Rouzier et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
